XML 23 R2.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Current assets    
Cash and cash equivalents $ 2,906.5 $ 2,938.0
Short-term investments (Note 5) 1,346.2 1,288.3
Accounts receivable, net of allowances of $16.0 and $15.0, respectively 770.4 659.6
Other receivables 185.3 252.5
Inventories (Note 2) 1,131.2 1,126.2
Prepaid expenses 119.0 135.0
Other current assets 360.3 339.3
Total current assets 6,818.9 6,738.9
Long-term investments (Note 5) 244.1 278.6
Property, plant, and equipment, net 1,841.8 1,811.9
Operating lease right-of-use assets 100.3 102.7
Goodwill 1,951.2 1,768.6
Other intangible assets, net 1,382.6 1,128.2
Deferred income taxes 911.8 1,138.1
Other assets (Note 2) 616.4 730.2
Total assets 13,867.1 13,697.2
Current liabilities    
Accounts payable 210.5 227.5
Accrued and other liabilities (Note 2) 1,273.3 1,561.7
Operating lease liabilities 24.1 24.5
Total current liabilities 1,507.9 1,813.7
Long-term debt 598.7 598.3
Operating lease liabilities 81.6 82.6
Uncertain tax positions 572.2 502.7
Other liabilities 381.8 362.3
Total liabilities 3,142.2 3,359.6
Commitments and contingencies (Note 12)
Stockholders' equity    
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding 0.0 0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 661.7 and 658.7 shares issued, and 576.6 and 580.7 shares outstanding, respectively 661.7 658.7
Additional paid-in capital 2,975.9 2,768.4
Retained earnings 14,863.1 14,240.5
Accumulated other comprehensive loss (Note 13) (214.6) (238.3)
Treasury stock, at cost, 85.1 and 78.0 shares, respectively (7,668.1) (7,091.7)
Total Edwards Lifesciences Corporation stockholders' equity 10,618.0 10,337.6
Noncontrolling interest 106.9 0.0
Total stockholders' equity 10,724.9 10,337.6
Total liabilities and equity $ 13,867.1 $ 13,697.2